Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
62 results about "Mammary cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Putting the definitions together, mammary epithelial cells are cells in the thin layer of tissue that coat and lines the surface of the milk ducts in the breast.
Beta-catenin is a strong and independent prognostic factor for cancer
InactiveUS20030064384A1Poor prognosisStrong and independent prognostic factor in cancerGenetic material ingredientsMicrobiological testing/measurementTransactivationFactor ii
Cyclin D1 is one of the targets of beta-catenin in breast cancer cells. Transactivation of beta-catenin correlated significantly with cyclin D1 expression both in eight breast cell lines in vitro and in 123 patient samples. More importantly, high beta-catenin activity significantly correlated with poor prognosis of the patients and is a strong and independent prognostic factor in breast cancer (p<0.001). Moreover, by multivariate analyses, the inventors found that activated beta-catenin is a strong prognostic factor which provided additional and independent predictive information on patients survival rate even when other prognostic factors, including lymph node metastasis, tumor size, estrogen receptor and progesterone receptor status, were taken into account (p<0.001). This invention demonstrates that beta-catenin is involved in breast cancer formation and / or progression and may serve as a target for breast cancer therapy.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Preventative effects of morinda citrifolia on mammary breast cancer
InactiveUS20050037101A1Avoid conversionInhibit mammary tumor growthBiocideUnknown materialsCarcinogenLymphatic Spread
The present invention features a novel use of processed ingredients from the Indian mulberry plant. More specifically, the present invention features a novel use of processed Morinda citrifolia, namely Morinda citrifolia fruit juice, puree, or puree juice for treating breast cancer, and particularly for inhibiting and / or preventing the metastasis of carcinogenic cells within the mammary region of the breast, as well as destroying metastasized mammary or breast cancer cells. The present invention comprises the consumption of food products or medicinal products or compositions comprising processed Morinda citrifolia, in either puree or fruit juice form. The present invention also features a method of inhibiting carcinogen-mediated conversion of mammary cells and protecting DNA against carcinogen-mediated damage by administering a composition comprising water soluble Morinda citrifolia.
Owner:TAHITIAN NONI INT INC
Chinese herbal medicine feed additive for improving milk yield of dairy cattle and improving dairy quality
ActiveCN104304749AIncrease milk productionImprove qualityFood processingAnimal feeding stuffBiotechnologyAngelica Sinensis Root
The invention discloses a Chinese herbal medicine feed additive for improving milk yield of dairy cattle and improving dairy quality. The additive contains fermented Chinese herbal medicine compounds with the effects of clearing away heat and toxic materials, invigorating the circulation of blood and promoting lactation, dilating blood vessels, tonifying kidney, qi and spleen and enhancing the body resistance, and sodium selenite and other substances capable of promoting milk yield of dairy cattle are added, and the absorption effect of the dairy cattle on additives and active ingredients can be improved due to existence of probiotics. The Chinese herbal medicine raw materials disclosed by the invention mainly comprise angelica sinensis, astragalus, acanthopanax, Beautiful Sweetgum Fruit, Codonopsis pilosula, the seed of cowherb, sea-buckthorn, dried tangerine or orange peel, motherwort, dandelion, Ligusticum wallichii, liquorice, fevervine and white paeony root. According to the Chinese herbal medicine feed additive, the mammary gland functions can be effectively improved, mammary gland cells are activated, the lactation yield of dairy cattle is improved, the milk production peak is maintained, the milk production quality is improved, and the product is environmentally and safe and does not have the problems of drug residues and drug tolerance.
Owner:广东广牧动物保健品有限公司
Traditional Chinese medicinal composition for treating breast cancer and preparation method thereof
InactiveCN102178818AImprove securityHigh feasibilityAnthropod material medical ingredientsAerosol deliveryLife qualityTherapeutic effect
The invention discloses a traditional Chinese medicinal composition for treating breast cancer. In the traditional Chinese medicinal composition, the oral medicament is prepared from white peony root, pilose asiabell root, astragalus root, angelica, rhizoma drynariae, spica prunellae, radix gentianae, lithosperm root, rhizoma atractylodis macrocephalae, gamboges, scorpion, Tuckahoe, lumbricus, Chinese sage herb, fructus psoraleae, frankincense, nutgrass galingale rhizome and rhizoma paridis; and the external medicine is prepared from arisaema tuber, red sage root, prepared kusnezoff monkshood root, dahurian patrinia herb, suberect spatholobus stem, giant typhonium rhizome, frankincense, myrrh, szechuan lovage rhizome, mongolian dandelion herb, dahurian angelica, scorpion and ginger. The traditional Chinese medicinal composition has the advantages of strong targeting property with direct access to affected parts, low cost and the like, and is convenient for administration and manufacture. The traditional Chinese medicinal composition has the beneficial effects that traditional Chinese medicinal materials with different medicine properties are scientifically combined so as to reach ideal and safe therapeutic effect; by adopting oral and external administration modes, antitumor function can be realized, mammary tumor cells are eliminated and bone metastasis is inhibited, thus improving symptoms of a patient maximally, enhancing life quality and prolonging life; and the composition has low cost and is convenient to use, thus creating higher social value and higher economic benefit.
Owner:潘国芬
Recombinant plasmid of GSDMD-N (gasdmermin D-N) gene, expression method in mammary gland and application
InactiveCN109136265APrevent proliferationAntibacterial agentsPeptide/protein ingredientsBacteroidesStaphylococcus cohnii
The invention discloses a recombinant plasmid of a GSDMD-N (gasdmermin D-N) gene, an expression method in mammary gland and an application, and belongs to the field of genetic engineering. An expression recombinant plasmid of the GSDMD-N gene is constructed and enabled to be specifically expressed in breast tissue and breast cells, so that mastitis caused by staphylococcus aureus infection is prevented and treated. GSDMD-N protein is a polypeptide compound found in recent years, which can specifically recognize biofilm component cardiolipin of bacteria and can be combined with cardiolipin to form a plurality of honeycomb-shaped pores, so that bacteria are disintegrated and die. According to the technology, the exogenous gene GSDMD-N is efficiently expressed in animal mammary glands througha specific promoter WAP (whey acidic protein) of breast tissue by a mammary bioreactor, staphylococcus aureus causing cow mastitis is killed, and accordingly, the cow mastitis caused by staphylococcus aureus infection is prevented and treated. The recombinant plasmid and the recombinant attenuated salmonella have the advantages of being efficient, safe, low in cost and the like, provide a a new approach for prevention and control of the cow mastitis caused by staphylococcus aureus infection, and have good application prospect.
Owner:JILIN UNIV
Suprabasal breast cell with stem cell properties
A method for isolating cells which have a suprabasal position and expresses epithelial specific antigen but no sialomucin is provided. The isolated cells are shown to share many of the properties expected of a mammary gland stem cell. Three permanent cell lines that are capable of proliferating and capable of differentiating into cells of mammary gland luminal epithelial and myoepithelial cell lineages were established. Such cells form elaborate branching structures resembling uncultured terminal duct lobular units both by morphology and marker expression both in vitro and in vivo. Evidence is provided that these keratin K19 expressing cells most probably is the cells in which breast cancer arises. Thus they constitute a model not only for the developing breast, but also for the development of breast cancer. Also disclosed are the uses of such isolated cells or the cell lines as a model system of the mammary gland for pharmacological studies and their uses in tissue repair or transplantation.
Owner:UNIVERSITY OF COPENHAGEN +1
Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
InactiveUS7537891B2Improved prognosisContinue treatmentSugar derivativesPeptide/protein ingredientsDisease areaProtein-Tyrosine Kinases
The present invention describes polynucleotides that have been discovered to correlate to the relative sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. Such polynucleotides comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through one or more of the aforementioned Src tyrosine and protein tyrosine kinases is involved with the disease process.
Owner:BRISTOL MYERS SQUIBB CO
Tissue diagnostics for breast cancer
InactiveUS20070111244A1Microbiological testing/measurementBiological material analysisProtein markersMammary cells
Disclosed are methods for diagnosing breast cancer in a cell sample by detecting an increase in the levels of expression of protein markers in the cell sample as compared to the levels of expression of the same protein markers in a normal, nonneoplastic breast cell sample. Also disclosed is a device for diagnosis of cancer in a cell sample.
Owner:AURELIUM BIOPHARMA
Live cell constructs for production of cultured milk product and methods using the same
This invention relates to live cell constructs for in vitro and / or ex vivo production of cultured milk products from mammary cells, methods of producing isolated cultured milk products from mammary cells, bioreactors for producing isolated cultured milk products, and cultured milk products.
Owner:BIOMILQ INC
Separation and culture method for different cellular components of human mammary tissue
InactiveCN104480062AThe method of isolation and culture is simple and easyGood cell modelArtificial cell constructsSkeletal/connective tissue cellsCellular componentLow speed
The invention relates to a separation and culture method for different cellular components of a human mammary tissue, and belongs to the technical field of cell culture. The method comprises the following steps: (1) sampling a fresh human mammary tissue specimen; (2) carrying out mechanical shearing and collagenase and hyaluronidase combined digestion to prepare a mammary tissue cell suspension; (3) carrying out low-speed and differential centrifugation to layer and separate the different cellular components; (4) carrying out centrifugation, washing and adherent culture for multiple times to purify the cell components, so as to obtain the different cellular components of the mammary tissue, which comprise epithelial cells, matrix cells and preadipocytes. The separation and culture method disclosed by the invention can be used for quickly, simply and effectively separating and purifying the different cellular components from the same mammary tissue; the cultured mammary gland cells are sufficient in quantity, good in cell viability and purity which is up to 95% above; the separation and culture method can provide very useful materials for molecular biology study associated with mammary glands and breast cancer, and establishes a foundation for construction of a mammary gland microenvironment multi-cell culture model.
Owner:GUANGDONG OCEAN UNIVERSITY
Kits and Methods for Identification, Assessment, Prevention and Therapy of Breast Cancer
InactiveUS20070243540A1Accurately determineOverall view of the potential pathology of the breastMicrobiological testing/measurementBiological testingNormal levelOncology
Disclosed herein are methods for detecting and identifying potential breast cancer biomarkers in an individual patient. Also disclosed are newly discovered breast cancer markers set forth in Tables I, II and III, associated with the cancerous state of breast cells. It has been discovered that a higher than normal level of expression of any of these markers or combination of these markers correlates with breast cancer in a patient. Methods are provided for detecting the presence of breast cancer in a sample, the absence of breast cancer in a sample, the stage of breast cancer, assessing whether a breast cancer has metastasized, predicting the likely clinical outcome of a breast cancer patient, and with other characteristics of breast cancer that are relevant to prevention, diagnosis, characterization, and therapy of breast cancer in a patient.
Owner:NORTHEASTERN UNIV
Live cell constructs for production of cultured milk product and methods using the same
ActiveUS11111477B2Increase rate increaseMilk preparationEpidermal cells/skin cellsBiotechnologyDairy foods
This invention relates to live cell constructs for in vitro and / or ex vivo production of cultured milk products from mammary cells, methods of producing isolated cultured milk products from mammary cells, bioreactors for producing isolated cultured milk products, and cultured milk products.
Owner:BIOMILQ INC
Substrate and method for culturing breast cells
InactiveUS20100297675A1Easy to handleImprove the bactericidal effectEpidermal cells/skin cellsDrug screeningPorous substrateNon malignant
A cell culture article includes a porous substrate having a plurality of pores and a plurality of interstices in communication with the pores. At least some of the plurality of pores and interstices are sufficiently large for two or more mammary epithelial cells to cluster within the pores or interstices. Non-malignant mammary epithelial cells or breast cancer cells may not attach strongly to the substrate surface, which may encourage cell-cell interaction. In many cases, the article is desirably free of components of unknown origin. The articles may be capable of maintaining culture of malignant and non-malignant mammary epithelial cells and allowing for development of in vivo-like morphologies or characteristics of such cells.
Owner:CORNING INC
General-purpose highly effective eukaryon expression carrier p3I-GFPN and mastitis-resisting transgene carrier constructed by the same
InactiveCN101186925ANot easy to accumulateFew cellsGenetic material ingredientsSexual disorderInterferonDomestic animal
The invention discloses a universal efficient eukaryotic expression vector p3I-GFPN and an anti-mastitis transgenic vector which is constructed by employing the vector. The anti-mastitis transgenic vector pCMV / CSN2-hLY-hIFA constructed by the invention can express green fluorescent protein at a high level in mammary gland cell. In the mammary gland cell of lactation period, initiation effect exerted by promoter of CSN2 enables the mammary gland cell of transformed pCMV / CSN2-hLY-hIFA to secrete a plurality of human lysozyme and human interferon A, and achieve target protein via breast milk separation and preferably fight against mastitis of livestock simultaneously.
Owner:NORTHWEST A & F UNIV
Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
InactiveUS7504211B2Modulate effectImproved prognosisPeptide/protein ingredientsMicrobiological testing/measurementDisease areaProtein-Tyrosine Kinases
The present invention describes polynucleotides that have been discovered to correlate to the relative sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. Such polynucleotides comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through one or more of the aforementioned Src tyrosine and protein tyrosine kinases is involved with the disease process.
Owner:BRISTOL MYERS SQUIBB CO
Application of set of miRNAs in preparation of marker for screening early-stage breast cancers
PendingCN111154878ADetect riskExpected riskMicrobiological testing/measurementDNA/RNA fragmentationEarly breast cancerMammary cells
The invention discloses application of a set of miRNAs in preparation of a marker for screening early-stage breast cancers. The invention discovers that free miRNAs with completeness and relative abundance quite accordant with mammary gland cells exist in human breast milk for the first time. Through comparison with abnormal miRNAs which are abnormally expressed by the breast cancers and are confirmed by existing researches, a set of breast milk free miRNAs suitable for potential application of the screening of the early-stage breast cancers are analyzed, 26 miRNAs are expected to be regulatedup in the development process of the early-stage breast cancers, and 12 miRNAs are expected to be regulated down in the development process of the early-stage breast cancers. The invention disclosesa theoretically feasible application detection scheme. By taking breast milk as a sample, the affection risk of the early-stage breast cancers is detected by detecting free miRNA markers related withthe breast cancers in the breast milk.
Owner:北京粒基生物科技有限公司 +1
Methods and compositions for diagnosing breast cancer
InactiveUS7332287B2Growth inhibitionPeptide/protein ingredientsGenetic material ingredientsPhosphorylationMammastatin
Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.
Owner:RGT UNIV OF MICHIGAN
Modified colony assay
InactiveUS20070059778A1Preventing and suppressing developmentPrevents background colony formationBiological testingProgenitorAntigen
Improved colony forming cell (CFC) assays are described. The improved assay comprises modifications to the standard CFC assay that enable analysis of temporal, real-time changes in antigen expression during colony development without need to fixate or destroy the culture. The improved assay is applicable to hematopoietic CFC assays as well as to CFC assays for other cells, such as neural cells and mammary cells. In one embodiment, the invention comprises adding a detection reagent, most likely a fluorescently labeled antibody, that is specific for antigens (most likely a cell-surface antigen) expressed on progenitors or on specific mature cell types to a culture at the start or during culture. The invention also comprises modifications to the culture medium and cell preparations used in standard CFC assays to selectively promote the development of one colony type while preventing or suppressing the development of other colony types.
Owner:STEMCELL TECHNOLOGIES
Nucleotide and protein sequence of mammastatin and methods of use
InactiveUS7256277B2Growth inhibitionPeptide/protein ingredientsAntibody mimetics/scaffoldsPhosphorylationADAMTS Proteins
A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.
Owner:RGT UNIV OF MICHIGAN
Composition capable of enlarging and beautifying breasts, cream and preparation and use methods of cream
InactiveCN107362101APromote blood circulationImprove microcirculationCosmetic preparationsToilet preparationsMaldevelopmentLepidium meyenii
The invention discloses a composition capable of enlarging and beautifying breasts, cream and preparation and use methods of cream. The composition is prepared from Lepidium meyenii, dandelions, panax notoginseng, saffron crocus, Anoectochilus roxburghii, green tangerine peels, luffa vegetable sponge, radix rhapontici, swallowwort roots, pearl essence and artemisia argyi powder. The cream is further prepared from the composition. The invention further discloses preparation and use methods of the cream. The composition and the cream, disclosed by the invention, are completely free of hormones and have obvious effects of repairing mastatrophy, external expansion, drooping, flatness and wrinkling and beautifying, enlarging and nursing flat breasts caused by maldevelopment; the composition and the cream can be used for promoting secondary development of the breasts, activating mammary glandular cells through pyrogenic dressing, massage and negative pressure, promoting the blood circulation and rapid fat aggregation of the breasts, prompting mammary growth and enabling the breasts to be full, mellow, dense and compact. In the opinion of a pyrogenic-dressing stasis removing theory of traditional Chinese medicine, pure herb essences are used for dredging channels and collaterals of the breasts and activating blood circulation to dissipate blood stasis, and thus, the breasts can be healthily nursed.
Owner:臧子宜
Peptide ligand to impair cancer cell migration
ActiveUS20080207521A1Reduce exerciseImprove adhesionPeptide/protein ingredientsImmunoglobulinsSequence analysisTumor cell adhesion
Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a 13 peptide fragments were identified and investigated for their ability to mimic effects of the Wnt-5a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumourigenic breast cancer cell lines, both low in endogenous Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumour cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectable. However, formulation of the N—terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumour cell motility. The novel formyl-Met-Asp-Gly-Cys-Glu-Leu peptide ligand can serve as a lead substance for anti-metastatic treatment in the 50% of human breast cancers where the endogenous expression of Wnt-5a is reduced.
Owner:WNTRES
Methods for treating breast cancer using a mammary cell growth inhibitor
Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.
Owner:UNIV OF MICHIGAN THE
Culture method of Jinhua pig mammary gland epithelial cell line
InactiveCN104946579AHigh purityQuality improvementVertebrate cellsArtificial cell constructsBiotechnologyMammary gland structure
The invention discloses a culture method of a Jinhua pig mammary gland epithelial cell line. Jinhua pig lactation-period 21-day mammary tissues are subjected to primary culture and subculture to finally obtain the high-purity high-viability Jinhua pig mammary gland epithelial cell line. The mammary gland cell line belongs to the field of biology. The cultured mammary gland cell line is free of fibroblasts and other impure cells, and has high cell purity. The cryopreserved cells have stable quality. The viability of the cryopreserved and resuscitated cells can reach 90%. The cells grow stably after being subjected to subculture, and are suitable for large-scale culture. The cytological characteristic detection indicates that the cell line satisfies the cell line establishment requirement. The Jinhua pig mammary gland epithelial cells can be used for preparing a nucleus transplantation donor of a transgenic pig. The Jinhua pig mammary gland epithelial cell line can provide a raw material for research in medicine and molecular biology. The Jinhua pig mammary gland epithelial cell line can enrich and improve the local pig species in agriculture, and is an effective protection means for favorable pig species in China.
Owner:ZHEJIANG UNIV
Method of the discrimination and isolation of mammary epithelial stem and colony-forming cells
The present invention relates to an improved method that permits the differential isolation of mouse mammary stem cells and colony forming cells (CFCs). The method involves depletion of non-epithelial cells from freshly dissociated mouse mammary tissue by incubation with an antibody composition containing antibodies specific for CD45, Ter119, CD35 and optionally CD140a. After formation of conjugates between the non-epithelial mammary cells and the antibodies specific for CD45, Ter119, CD35 and optionally CD140a, the cell conjugates are removed and the remaining epithelial cells are then incubated with an antibody composition containing antibodies specific for CD24 and CD49f. After formation of conjugates between the epithelial cells and the antibodies specific for CD24 and CD49f, the mouse mammary stem and the luminal-restricted CFC cells can be differentially isolated. The invention also relates to kits for carrying out this method and to the cell preparations prepared by this method.
Owner:STEMCELL TECHNOLOGIES +1
Method for inducing differentiation of iPS cells to mammary glands in vitro and special culture medium for method
ActiveCN111235112ASuitable for establishmentHigh differentiation efficiencyGenetically modified cellsEpidermal cells/skin cellsBiotechnologyMammary cells
The invention discloses a method for inducing differentiation of iPS cells to mammary glands in vitro and a special culture medium for the method. The in-vitro induction method comprises the followingsteps: dissociating the iPS cell into single cells, inoculating an iPS cell maintaining culture medium with the single cells as seed cells, and obtaining high-density monolayer cells; culturing the monolayer iPS cells in a differentiation culture medium I, and changing solutions for the cells every day; discarding the culture medium, culturing the cells with a differentiation culture medium II, and changing solutions for the cells every other day; discarding the culture medium, culturing the cells with a differentiation culture medium III, and changing solutions for the cells every other day;and discarding the culture medium, and continuously culturing the cells with a differentiation culture medium IV. The method can obtain a large quantity of single mammary gland cells at different differentiation stages, has the advantages of being simple to operate, low in cost, high in differentiation efficiency and the like, and has broad application prospects.
Owner:SUN YAT SEN UNIV
Codon optimized recombinant human lysozyme gene and application thereof
ActiveCN108624606AObvious preferenceReduce frequency of useNucleic acid vectorFermentationWild typeLysobacter enzymogenes
The invention relates to codon optimized recombinant human lysozyme gene and application thereof. The codon optimized recombinant human lysozyme gene is characterized in that human lysozyme codons aresubjected to global optimization (Lyzop) by comparing bovine mammary superior milk protein high-frequency codons and low-frequency codons, and optimization (Lyzop23) is performed by interpreting initial post 23-bit codons. The optimized codons obviously improve the human lysozyme mRNA stability and the mRNA expression quantity in bovine mammary cells. Western immunoblotting experiments prove thatthe expression quantity of the codon optimized recombinant human lysozyme gene in the bovine mammary cells is 2.18 times of that of wild types. Tool gene is provided for efficiently producing the recombinant human lysozyme by a cell bioreactor and a bovine mammary bioreactor in future. Meanwhile, the codon optimized recombinant human lysozyme gene and luciferase are fused for expression; by analyzing the luciferase expression quantity, the fast and accurate evaluation on the codon optimizing effect is realized; a novel reliable evaluation method is provided for developing the gene codon optimization in the future.
Owner:NORTHWEST A & F UNIV
Pharmaceutical product and analysis model for hormone replacement therapy for women and prevention of some cancers and uterine myomas
The present disclosure describes a study of estrogenic activity present in various plant species, selectively inducing some but not all estrogenic responses in the uterus. Prepubertal female rats were treated sequentially with various extracts or decoctions of different plant species or its vehicle, followed 1 h later by treatment with estradiol-17β (E) or its solvent. Uteri were excised under anesthesia and histologically processed for eosinophil quantification and morphometric evaluation of various uterine responses to estrogen, at 6 or 24 h after hormone or vehicle treatment. Besides extracts or decoctions, pure phytoestrogens were also used. Additionally, human mammary cancer cells MCF-7 or MDAMB-231 were cultured in presence of the extract (or decoction), E, both or solvent and cell proliferation was evaluated. Various extracts or decoction displayed selective estrogenic and / or antiestrogenic action for some but not all parameters of estrogen stimulation in the uterus and inhibited growth of human mammary cells in culture or antagonized the estrogen-induced increase in their growth. Present results reveal, for the first time, a dissociation of responses to estrogen by phytoestrogens, suggesting its possible therapeutic application as estrogenic compounds not inducing cell proliferation and reveal the anticancerous effect of some of the extracts with possible therapeutic relevance. The dissociation of responses to estrogen additionally suggest therapeutic applications in estrogen-related diseases (for instance, premenstrual syndrome, endometriosis, etc.); the inhibition of eosinophil degranulation suggest an application in diseases related to eosinophils (hypereosinophilic syndrome, allergic and hypersensitivity diseases).
Owner:CHERNIKALIFE +1
Ten-medicine Xiang Lu capsule, preparation method thereof and ginsenoside content analysis method
InactiveCN110917313AReduce the numberReduce usageComponent separationUnknown materialsFormularyEstradiolum
The invention discloses a ten-medicine Xiang Lu, a preparation method thereof and a ginsenoside content analysis method, and belongs to the technical field of traditional Chinese medicine formulas. The capsule gives full play to the values of the traditional Chinese medicines, has the effects of soothing liver-qi stagnation, softening hardness to dissipate stagnation and the like, the pharmacodynamic material basis of ginseng is ginsenoside which has an adjusting effect on the neuroendocrine function of the pituitary-gonad axis and can excite the pituitary to secrete gonadotropin, promote biosynthesis of DNA and protein synthesis related zymoprotein and increase the gonad activity. Through the two-way regulation effect on the pituitary-gonad axis, the positive and negative feedback functions of neuroendocrine are balanced so as to achieve the purpose of reducing estradiol which is abnormally increased, and mammary gland cell proliferation controlled by ovarian hormone is inhibited; andinternal components of traditional Chinese medicines are selected as internal standards in a quantitative analysis of multiple components by single marker, and the content of the to-be-detected components is calculated by measuring relative correction factors (RCF) between the internal standards and other to-be-detected components, so that the use amount of reference substances is reduced, and the cost is saved.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE
Pharmaceutical product and analysis model for hormone replacement therapy for women and prevention of some cancers and uterine myomas
The present disclosure describes a study of estrogenic activity present in various plant species, selectively inducing some but not all estrogenic responses in the uterus. Prepubertal female rats were treated sequentially with various extracts or decoctions of different plant species or its vehicle, followed 1 h later by treatment with estradiol-17β (E) or its solvent. Uteri were excised under anesthesia and histologically processed for eosinophil quantification and morphometric evaluation of various uterine responses to estrogen, at 6 or 24 h after hormone or vehicle treatment. Besides extracts or decoctions, pure phytoestrogens were also used. Additionally, human mammary cancer cells MCF-7 or MDAMB-231 were cultured in presence of the extract (or decoction), E, both or solvent and cell proliferation was evaluated. Various extracts or decoction displayed selective estrogenic and / or antiestrogenic action for some but not all parameters of estrogen stimulation in the uterus and inhibited growth of human mammary cells in culture or antagonized the estrogen-induced increase in their growth. Present results reveal, for the first time, a dissociation of responses to estrogen by phytoestrogens, suggesting its possible therapeutic application as estrogenic compounds not inducing cell proliferation and reveal the anticancerous effect of some of the extracts with possible therapeutic relevance. The dissociation of responses to estrogen additionally suggest therapeutic applications in estrogen-related diseases (for instance, premenstrual syndrome, endometriosis, etc.); the inhibition of eosinophil degranulation suggest an application in diseases related to eosinophils (hypereosinophilic syndrome, allergic and hypersensitivity diseases).
Owner:CHERNIKALIFE +1
Method for analyzing content of ginsenoside in ten-ingredient Xiangdeer capsule
ActiveCN113866288AReduce the numberReduce usageComponent separationAgainst vector-borne diseasesFormularyPhysiology
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com